| Zugriffe | |
|---|---|
| KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 188 |
| Juni 2024 | Juli 2024 | August 2024 | September 2024 | Oktober 2024 | November 2024 | Dezember 2024 | |
|---|---|---|---|---|---|---|---|
| KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 2 | 4 | 1 | 5 | 6 | 2 | 3 |
| Zugriffe | |
|---|---|
| 2021_Frost_etal.pdf | 157 |
